Skip to main content
. 2011 Aug 2;459(3):283–289. doi: 10.1007/s00428-011-1132-8

Fig. 3.

Fig. 3

A high degree of variability between institutes was observed with regard to the HER2 2+ category. In particular, the differentiation between HER2 2+ and HER2 1+ might be handled differently. This case illustrates the borderline between the 2+ category (intraductal carcinoma, double arrow) and the 1+ category (invasive carcinoma, single arrow) (immunohistochemistry with 4B5 anti-HER2 monoclonal antibody, ×200)